Ib tug puv tes ntawm biotech thiab cov khoom kho mob tau koom nrog cov neeg tseem ceeb IBD 50 daim ntawv teev npe, khav theeb muaj zog thiab muaj peev xwm loj hlob. Cov pab pawg thawj coj hauv kev lag luam no tau ua pov thawj cov neeg yeej tau txais ob tus lej rov qab rau xyoo 2022.
X
Genmab (GMAB) tau ntxiv rau IBD 50 Top 10 daim ntawv teev npe lub lim tiam no. Medpace (MEDP) kuj tau ntxiv rau daim ntawv teev npe no thiab IBD's Leaderboard. Lwm cov neeg ua yeeb yam zoo tshaj suav nrog Catalyst Pharmaceuticals (CPRX) thiab Txhawb Kev Kho Mob (QHIB).
Cov khoom lag luam biotech thiab kev kho mob tau pib poob qis thaum Lub Ob Hlis 2021 thiab ntaus nqi qis tshiab rau lub caij ntuj sov no. Lawv khi nrog kev khiav tsis tu ncua mus txog Lub Yim Hli thiab rub rov qab, kev lag luam sab hauv mus rau xyoo kawg. Cov pab pawg no tau pom tias yog kev tiv thaiv kev ua si thiab qhov chaw zoo rau cov tub ua lag luam los nres lawv cov nyiaj ntsuab.
Ib qho khoom lag luam txuas ntxiv, lwm qhov yuav tsum tau them nyiaj hauv
Catalyst yog ncua los ntawm lub 5% yuav zone ntawm a khob-nrog-kuav puag nrog muas point ua 16.76. Tus kws tsim tshuaj tsis tshua muaj kab mob ua kom nrawm EPS thiab kev muag khoom loj hlob hauv peb lub hlis twg dhau los.
Cov Tshuag tau trending upward txij thaum ib zoo Q3 daim ntawv qhia nyiaj tau los thaum lub Kaum Ib Hlis. Shares tau nce ib qho impressive 180% xyoo rau hnub tim.
Cov kws tshuaj ntsuam xav tias txhua xyoo EPS kev loj hlob ntawm 33% hauv 2022 thiab 66% hauv 2023. Catalyst yog thawj zaug hauv 800 muaj zog Medical-Biomed / Biotech kev lag luam pawg, uas yog ranked 30th tawm ntawm 197 IBD stocks.
Medpace tab tom sim tsim kom muaj kev sib koom ua ke tshiab puag tom qab tawg tawm ntawm lub khob qauv tom qab zoo tshaj qhov xav tau Q3 cov nyiaj tau los thiab kev muag khoom thaum lub Kaum Hlis. Lub biotech tshwj xeeb hauv kev tshawb fawb rau tshuaj thiab khoom siv kho mob, thiab kev tswj xyuas kev kuaj mob. Cov khoom lag luam rub rov qab thiab tau nyob rau hauv kev lag luam tsis hloov pauv txij li kev tawg.
Inspire Medical yog nyob rau hauv 20% mus rau 25% profit zone tom qab ntaus tus 212.22 buy point ntawm a ob-hauv qab puag. Shares tawg tawm tom qab tshaj tawm qhov poob qis dua Q3 thiab siab dua qhov kev muag khoom ntawm Lub Kaum Ib Hlis 1.
Lub tuam txhab tsim tsuas yog FDA pom zoo implanted pw tsaug zog apnea ntaus ntawv. Inspire tseem tsis tau muaj txiaj ntsig.
Inspire tau qhia txog kev muag khoom zoo li peb lub hlis twg hauv 70% ntau rau tsib lub hlis dhau los.
Mutual funds muaj 77% ntawm INSP shares, nrog 580 tus tswv shares nyob rau hauv lub Cuaj Hli Ntuj, nce los ntawm 565 nyob rau hauv Lub rau hli ntuj thiab 542 nyob rau hauv Lub peb hlis ntuj.
Lwm Yam Kub Biotech Thiab Kho Mob Tshuag
Denmark-based biotech thiab cov khoom kho mob Genmab tau qhia tias kev loj hlob ntawm peb lub hlis twg hauv kev muag khoom thiab EPS.
Kev sib koom ntawm tus kws kho mob qog noj ntshav no tau tshwm sim los ntawm qhov ntev, tob khob base tom qab qhov kev sim ua tsis tiav ntawm tus kov kom raug. GMAB poob qis dua nws 21-hnub exponential txav nruab nrab thiab kov cov 50-hnub txav nruab nrab, nrhiav kev txhawb nqa ntawm kab.
AstraZeneca (AZN) rub rov qab tom qab tawg tawm ntawm ob sab hauv qab hauv lub Kaum Ob Hlis. Shares tau dhia dej rau xov xwm lub tuam txhab cov tshuaj kho mob qog noj ntshav prostate yuav ntsib kev tshuaj xyuas txuas ntxiv los ntawm Food and Drug Association.
Thaum kawg, Neurocrine Kev Tshawb Fawb (NBIX) ua rau kev kho mob paj hlwb thiab kab mob endocrine, thiab nce yuav luag 41% xyoo rau hnub tim.
KOJ UA LI CAS:
Tau Txais IBD Cov Ntawv Xov Xwm Dawb: Ua Lag Luam Prep | Tech Qhia | Kev Ua Lag Luam Li Cas
YUAV UA LI CAS YOG SLIM? Yog Tias Koj Xav Pom Cov Txiaj Ntsim Zoo Tom Qab, Rov Tuaj Zoo Dua
Live IBD: Kawm Thiab Tshawb Kev Loj Hlob Cov Lus Cog Tseg Nrog Cov Pros
Cov cuab yeej MarketSmith tuaj yeem Pab Tus Kheej Cov Lag Luam
Nrhiav Rau Cov Tom Qab Loj Cov Khoom Lag Luam Loj Tshaj? Pib Nrog 3 Kauj Ruam No
Tau qhov twg los: https://www.investors.com/stock-lists/ibd-50/biotech-and-medical-stocks-leading-performers-as-2022-draws-to-a-close/?src=A00220&yptr=yahoo